GLPwatch

Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes

NCT02674893 · Terminated

Last updated 2026-05-28

This clinical trial tested whether Victoza, a medication for type 2 diabetes, affects food preferences and eating habits in adults with type 2 diabetes who are also overweight.

Status Terminated Stopped early and will not restart.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Participants 48 people
Who can join Ages 18+ · all sexes Healthy volunteers accepted.
Timeline Started 2014-02 · est. completion 2016-08
Where 1 site · France

What this study is testing ClinicalTrials.gov NCT02674893 ↗

Description as written by the study sponsor.

This is an open-label comparative study in three parallel groups. It is expected that 90 patients and/or healthy volunteers will participate in this biomedical research. Distribution in groups * 30 patients with type 2 diabetes and an indication for treatment with a GLP1 analogue (group 1) * 30 patients with type 2 diabetes (control diabetic subjects) not treated with Incretins (group 2) * 30 healthy subjects (non-diabetics) (group 3) This study will investigate modifications in eating behaviour induced by Liraglutide in patients who start treatment with Victoza® and certain aspects, such as liking (hedonic characteristic of a food), wanting (desire to eat a given food) and salivation in response to the presentation of a food by taking measurements at D0 (before initiation of the treatment with Liraglutide in the group concerned) then at 15 days (except for the controls), 3 months and 9 months (only for controls).

Treatments tested

Main thing measuredModifications in wanting
SponsorCentre Hospitalier Universitaire Dijon
Conditions studiedType 2 Diabetes, Overweight
GLP-1 drugs liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02674893 ↗